{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-066397","form_type":"8-K","ticker":"NUVL","cik":"0001861560","company_name":"Nuvalent, Inc.","filed_at":"2025-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:02:50.229261+00:00","generated_at":"2026-05-22T05:34:14.423972+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Nuvalent reports Q1 net loss $84.6M; reiterates zidesamtinib pivotal data in H1 2025, NDA by mid-2025","bullets":["Cash $1.1B at March 31, 2025; expected to fund operations into 2028.","Q1 net loss $84.6M; R&D expense $74.4M, G&A expense $20.4M.","Zidesamtinib pivotal data for TKI pre-treated ROS1+ NSCLC in H1 2025; NDA submission by mid-2025.","Neladalkib pivotal data for TKI pre-treated ALK+ NSCLC by year-end 2025; ALKAZAR Phase 3 start in H1 2025.","Leadership promotions: Ruth Adams to SVP Clinical Ops, Joshua Horan to SVP Chemistry, Jessie Lin to SVP Corporate Strategy."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-066397","json":"https://secwatch.observer/filing/0000950170-25-066397.json","markdown":"https://secwatch.observer/filing/0000950170-25-066397.md","text":"https://secwatch.observer/filing/0000950170-25-066397.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1861560/000095017025066397/0000950170-25-066397-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1861560/000095017025066397/nuvl-20250508.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T05:34:14.423972+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}